Lupus and Allied Diseases Association Donates $150,000 to Advance Lupus Research
Our deepest thanks go to the Lupus and Allied Diseases Association, Inc. (LADA) for their extremely generous donation of $150,000 to...
Hydroxycloroquine in COVID-19 Trial Restarted in UK
Hydroxycloroquine in COVID-19 Trial Restarted in UK
June 30, 2020
The British Medicines and Healthcare Products Regulatory Agency has approved the restart of a global trial that will explore whether the drugs hydroxychloroquine and chloroquine are able to prevent coronavirus infections.
Led by Oxford University’s Mahidol Oxford Tropical Medicine Research Unit, the randomized, placebo-controlled trial will enroll around 40,000 healthcare workers and other at-risk workers worldwide.
The regulatory agency had suspended enrollment into the trial after a paper was published in the medical journal Lancet showing an increased death risk linked to hydroxychloroquine. The Lancet retracted the paper when it was found to be based on suspicious data.
This news was reported by numerous media outlets including:
